Epigenetic modulation in cancer immunotherapy

Stuart J. Gallagher; Elena Shklovskaya; Peter Hersey

doi:10.1016/j.coph.2017.05.006

Epigenetic modulation in cancer immunotherapy

Stuart J. Gallagher, Elena Shklovskaya, Peter Hersey

Research output: Contribution to journal › Review article › peer-review

51 Citations (Scopus)

Abstract

The success of immune checkpoint inhibitors in cancer immunotherapy has been widely heralded. However many cancer patients do not respond to immune checkpoint therapy and some relapse due to acquired tumor resistance. Epigenetic targeting may be beneficial in cancer immunotherapy by reversing immune avoidance and escape mechanisms employed by cancer cells, as well as by modulating immune cell differentiation and function. In this manuscript we review recent findings suggesting how epigenetics may be used to improve cancer immunotherapy. We focus on the inhibitors of the CTLA4 and PD1 immune checkpoints and epigenetic modifiers of histone acetylation and methylation and DNA methylation.

Original language	English
Pages (from-to)	48-56
Number of pages	9
Journal	Current Opinion in Pharmacology
Volume	35
DOIs	https://doi.org/10.1016/j.coph.2017.05.006
Publication status	Published - 1 Aug 2017
Externally published	Yes

Access to Document

10.1016/j.coph.2017.05.006

Cite this

@article{353a36b3db3e4c708b1c850059e3a737,

title = "Epigenetic modulation in cancer immunotherapy",

abstract = "The success of immune checkpoint inhibitors in cancer immunotherapy has been widely heralded. However many cancer patients do not respond to immune checkpoint therapy and some relapse due to acquired tumor resistance. Epigenetic targeting may be beneficial in cancer immunotherapy by reversing immune avoidance and escape mechanisms employed by cancer cells, as well as by modulating immune cell differentiation and function. In this manuscript we review recent findings suggesting how epigenetics may be used to improve cancer immunotherapy. We focus on the inhibitors of the CTLA4 and PD1 immune checkpoints and epigenetic modifiers of histone acetylation and methylation and DNA methylation.",

author = "Gallagher, {Stuart J.} and Elena Shklovskaya and Peter Hersey",

year = "2017",

month = aug,

day = "1",

doi = "10.1016/j.coph.2017.05.006",

language = "English",

volume = "35",

pages = "48--56",

journal = "Current Opinion in Pharmacology",

issn = "1471-4892",

publisher = "Elsevier",

}

TY - JOUR

T1 - Epigenetic modulation in cancer immunotherapy

AU - Gallagher, Stuart J.

AU - Shklovskaya, Elena

AU - Hersey, Peter

PY - 2017/8/1

Y1 - 2017/8/1

N2 - The success of immune checkpoint inhibitors in cancer immunotherapy has been widely heralded. However many cancer patients do not respond to immune checkpoint therapy and some relapse due to acquired tumor resistance. Epigenetic targeting may be beneficial in cancer immunotherapy by reversing immune avoidance and escape mechanisms employed by cancer cells, as well as by modulating immune cell differentiation and function. In this manuscript we review recent findings suggesting how epigenetics may be used to improve cancer immunotherapy. We focus on the inhibitors of the CTLA4 and PD1 immune checkpoints and epigenetic modifiers of histone acetylation and methylation and DNA methylation.

AB - The success of immune checkpoint inhibitors in cancer immunotherapy has been widely heralded. However many cancer patients do not respond to immune checkpoint therapy and some relapse due to acquired tumor resistance. Epigenetic targeting may be beneficial in cancer immunotherapy by reversing immune avoidance and escape mechanisms employed by cancer cells, as well as by modulating immune cell differentiation and function. In this manuscript we review recent findings suggesting how epigenetics may be used to improve cancer immunotherapy. We focus on the inhibitors of the CTLA4 and PD1 immune checkpoints and epigenetic modifiers of histone acetylation and methylation and DNA methylation.

UR - http://www.scopus.com/inward/record.url?scp=85020376696&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2017.05.006

DO - 10.1016/j.coph.2017.05.006

M3 - Review article

C2 - 28609681

AN - SCOPUS:85020376696

SN - 1471-4892

VL - 35

SP - 48

EP - 56

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

ER -

Epigenetic modulation in cancer immunotherapy

Abstract

Access to Document

Other files and links

Fingerprint

Cite this